RxDoctor Payments Data

Victoria Arthur

Psychiatric/Mental Health · Oswego, NYNPI 1093359051

Payments from drug & device makers

$780in general payments, 2019–2025

Across 47 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$289
  • E.r. Squibb & Sons, L.L.C.$162
  • Indivior Inc.$158
  • Otsuka America Pharmaceutical, Inc.$141
  • AbbVie$30

What the payments were for

  • Food & beverage$780100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$780 in reported general payments places this provider in the 60th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$20,360
Medicare patients
46
Services billed
275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AristadaAripiprazole Lauroxil15$46,478
VraylarCariprazine Hcl31$41,975
PerserisRisperidone16$40,979
Invega SustennaPaliperidone Palmitate11$36,602
RexultiBrexpiprazole12$17,250
Aripiprazole179$12,589
Clozapine OdtClozapine23$8,714
Lurasidone Hcl43$3,725
Divalproex Sodium ErDivalproex Sodium94$3,285
Clozapine70$2,673
Olanzapine141$2,028
Sertraline Hcl247$1,988
Duloxetine Hcl45$1,785
Quetiapine Fumarate90$1,378
Risperidone126$1,377

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$30$41,97531 claims
Indivior Inc.Perseris$158$40,97916 claims
Otsuka America Pharmaceutical, Inc.Rexulti$141$17,25012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Oswego

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →